Stocklytics Platform
Asset logo for symbol NAMS
NewAmsterdam Pharma Company N.V.
NAMS52
$23.67arrow_drop_down3.66%-$0.89
High Growth
Asset logo for symbol NAMS
NAMS52

$23.67

arrow_drop_down3.66%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

NewAmsterdam Pharma Company N.V. (NAMS) Stocklytics Forecast

NewAmsterdam Pharma Company N.V. (NAMS) is a pharmaceutical company that specializes in developing innovative medical solutions. With a strong track record of success and a dedicated team of researchers, NAMS is poised for growth in the coming years. The company has a diversified portfolio of products, ranging from therapeutics for rare diseases to over-the-counter medications. This diverse offering allows NAMS to capture a wide range of market opportunities and provide value to both patients and healthcare providers.
One of the key factors driving NAMS' future success is its commitment to research and development. The company invests heavily in cutting-edge technologies and collaborative partnerships to stay at the forefront of medical advancements. By leveraging artificial intelligence and machine learning, NAMS is able to identify promising drug candidates and accelerate the development process. This strategic approach not only reduces costs but also increases the likelihood of successful clinical trials and regulatory approvals.
add NewAmsterdam Pharma Company N.V. to watchlist

Keep an eye on NewAmsterdam Pharma Company N.V.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for NewAmsterdam Pharma Company N.V. (NAMS) stock?

Analysts have set a target price of $25.43 for NewAmsterdam Pharma Company N.V. (NAMS), based on forecasts from 7 analysts. The predicted price range extends from a high of $37 to a low of $19. This represents a potential increase of up to 56.32% and a decrease of -19.73% from the current price of $23.67. These forecasts are as of 2019 Sep 24.
help

What are the analyst ratings for NewAmsterdam Pharma Company N.V. (NAMS) stock?

The analyst ratings for NewAmsterdam Pharma Company N.V. (NAMS) are distributed as follows: 9 analysts recommend buying, 0 have a neutral stance, and 0 suggest selling. There is a split consensus, with equal support for two of the rating categories. These ratings indicate the general sentiment among the analysts covering NewAmsterdam Pharma Company N.V..
help

What is the AI price prediction for NewAmsterdam Pharma Company N.V. (NAMS) stock?

At present, there is no AI or machine-learning-based price prediction available for NewAmsterdam Pharma Company N.V. (NAMS) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level